Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.59
- Piotroski Score 3.00
- Grade N/A
- Symbol (CYTO)
- Company Altamira Therapeutics Ltd.
- Price $0.44
- Changes Percentage (-0.55%)
- Change -$0
- Day Low $0.41
- Day High $0.44
- Year High $17.20
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/09/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$16.63
- Trailing P/E Ratio -0.09
- Forward P/E Ratio -0.09
- P/E Growth -0.09
- Net Income $-7,270,038
Income Statement
Quarterly
Annual
Latest News of CYTO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History
Bayer has acquired rights to Cytokinetics' heart drug in Japan through a collaboration deal. The agreement includes an upfront payment of 50 million euros with potential additional payments based on d...
By Yahoo! Finance | 3 days ago -
Bayer acquires rights to Cytokinetics' heart drug in Japan
Bayer collaborates with U.S. biotech firm Cytokinetics to acquire rights in Japan for an experimental heart drug, strengthening its cardiovascular business. The deal includes upfront payment of 50 mil...
By Yahoo! Finance | 3 days ago -
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
The CEO, Sean McCarthy, provided updates on CX-904 and CX-2051 programs, emphasizing dose escalation for CX-904 and progress into cohort five for CX-2051. Phase 1B decisions and updates are expected n...
By Yahoo! Finance | 2 weeks ago
